-+ 0.00%
-+ 0.00%
-+ 0.00%

ORIC Pharmaceuticals Presents Multiple Poster Presentation At 2026 American Association For Cancer Research Annual Meeting On Potential Of Rinzimetostat For Prostate Cancer Treatment

Benzinga·04/17/2026 20:07:04
Listen to the news

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer.